Drug Profile
Research programme: small molecule therapeutics - Chipscreen Biosciences
Alternative Names: CS 3158; CS 410; CS 510; CS-00018; CS-00088; CS-00098; CS-12328; CS-12629; CS00028; CS0220; CS0230; CS0240; CS0600; HDAC inhibitors - Chipscreen; Histone deacetylase inhibitors - Chipscreen Biosciences; Kinase inhibitors - Chipscreen Bioscience; VEGFR inhibitors - Chipscreen BiosciencesLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Chipscreen Biosciences
- Class Antihyperglycaemics; Antineoplastics; Cardiovascular therapies; Hepatoprotectants; Neuroprotectants; Small molecules
- Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors; Histone deacetylase inhibitors; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Janus kinase 3 inhibitors; MAP kinase kinase kinase 5 inhibitors; Peroxisome proliferator-activated receptor agonists; Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists; Retinoid X receptor agonists; Tryptophan oxygenase inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; Neurodegenerative disorders; Non-alcoholic fatty liver disease; Solid tumours; Type 2 diabetes mellitus
- Discontinued Viral infections
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in China
- 28 Jun 2023 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in China
- 28 Oct 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in China